Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder
Government-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. TAMPA, Fla., Oct. 8, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.